CRISPR Therapeutics AG (CRSP) Financials

CRSP Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 2.7 billion 904.2 million
March 31, 2026 2.7 billion 911.3 million
Dec. 31, 2025 2.3 billion 343.4 million
Sept. 30, 2025 2.2 billion 329.3 million

CRSP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -193.5 million 33.6 million
March 31, 2026 -109.4 million 16.3 million
Dec. 31, 2025 -93.1 million 18.1 million
Sept. 30, 2025 -84.7 million 16.6 million

CRSP Net Income

No data available :(

CRSP Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 2.4 billion 586.2 million 197.6 million
March 31, 2026 2.4 billion 585.5 million 202.2 million
Dec. 31, 2025 2.0 billion 188.2 million 188.2 million
Sept. 30, 2025 1.9 billion 192.8 million 192.8 million

CRSP Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 96.5 million
March 31, 2026 96.1 million
Dec. 31, 2025 89.9 million
Sept. 30, 2025 91.3 million

CRSP Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 1.2 million 65.0 million 15.5 million -
March 31, 2026 504000 68.6 million 17.2 million -
Dec. 31, 2025 517000 77.9 million 18.4 million -
Sept. 30, 2025 74000 58.9 million 16.9 million -

CRSP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 10.2 million 44.6 million
March 31, 2026 1.5 million 50.2 million
Dec. 31, 2025 864000 59.4 million
Sept. 30, 2025 889000 64.7 million

CRSP Revenue by Segment
Graph available only for paid members. Upgrade to see it.

CRSP

Price: $49.25

52 week price:
44.12
78.48

Earnings Per Share: -4.71 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: Switzerland

Volume: 1.2 million

Ebitda: -23.2 million

Market Capitalization: 5.3 billion

Links: